Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Burkitt Lymphoma 1

Interventions

Carboplatin 6Specimen Handling 5Rituximab 5amivantamab 4Prednisone 4olaparib 3lazertinib 3acalabrutinib 3X-Rays 3Pemetrexed 3Nivolumab 3Magnetic Resonance Spectroscopy 3Dexamethasone 3Cyclophosphamide 3Ado-Trastuzumab Emtansine 3Abiraterone Acetate 3trastuzumab deruxtecan 2talquetamab 2pertuzumab 2pembrolizumab 2osimertinib 2niraparib 2ipatasertib 2erdafitinib 2entrectinib 2durvalumab 2daratumumab 2belzutifan 2atezolizumab 2apalutamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × N,N-dicyclohexyl-isoborneol-10-sulfonamide × 30 days × Clear all
NCT02003222 2026-05-28

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
488 enrolled 13 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡